IPO Year: 2022
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/9/2024 | $12.00 → $20.00 | Equal-Weight → Overweight | Morgan Stanley |
| 6/18/2024 | $23.00 | Buy | Stifel |
| 6/7/2024 | $18.00 | Outperform | Raymond James |
Morgan Stanley upgraded Third Harmonic Bio from Equal-Weight to Overweight and set a new price target of $20.00 from $12.00 previously
Stifel initiated coverage of Third Harmonic Bio with a rating of Buy and set a new price target of $23.00
Raymond James initiated coverage of Third Harmonic Bio with a rating of Outperform and set a new price target of $18.00
4 - Third Harmonic Bio, Inc. (0001923840) (Issuer)
4 - Third Harmonic Bio, Inc. (0001923840) (Issuer)
4 - Third Harmonic Bio, Inc. (0001923840) (Issuer)
4 - Third Harmonic Bio, Inc. (0001923840) (Issuer)
4 - Third Harmonic Bio, Inc. (0001923840) (Issuer)
4 - Third Harmonic Bio, Inc. (0001923840) (Issuer)
4/A - Third Harmonic Bio, Inc. (0001923840) (Issuer)
4 - Third Harmonic Bio, Inc. (0001923840) (Issuer)
4 - Third Harmonic Bio, Inc. (0001923840) (Issuer)
4 - Third Harmonic Bio, Inc. (0001923840) (Issuer)
SC 13G/A - Third Harmonic Bio, Inc. (0001923840) (Subject)
SC 13G - Third Harmonic Bio, Inc. (0001923840) (Subject)
SC 13D/A - Third Harmonic Bio, Inc. (0001923840) (Subject)
SC 13G/A - Third Harmonic Bio, Inc. (0001923840) (Subject)
SC 13D/A - Third Harmonic Bio, Inc. (0001923840) (Subject)
SC 13G - Third Harmonic Bio, Inc. (0001923840) (Subject)
SC 13G/A - Third Harmonic Bio, Inc. (0001923840) (Subject)
SC 13G/A - Third Harmonic Bio, Inc. (0001923840) (Subject)
SC 13G - Third Harmonic Bio, Inc. (0001923840) (Subject)
SC 13G - Third Harmonic Bio, Inc. (0001923840) (Subject)
8-K - Third Harmonic Bio, Inc. (0001923840) (Filer)
10-Q - Third Harmonic Bio, Inc. (0001923840) (Filer)
144 - Third Harmonic Bio, Inc. (0001923840) (Subject)
144 - Third Harmonic Bio, Inc. (0001923840) (Subject)
8-K - Third Harmonic Bio, Inc. (0001923840) (Filer)
10-Q - Third Harmonic Bio, Inc. (0001923840) (Filer)
8-K - Third Harmonic Bio, Inc. (0001923840) (Filer)
8-K - Third Harmonic Bio, Inc. (0001923840) (Filer)
10-Q - Third Harmonic Bio, Inc. (0001923840) (Filer)
ARS - Third Harmonic Bio, Inc. (0001923840) (Filer)
Stifel analyst Alex Thompson initiates coverage on Third Harmonic Bio (NASDAQ:THRD) with a Buy rating and announces Price Target of $23.
Raymond James analyst Laura Prendergast initiates coverage on Third Harmonic Bio (NASDAQ:THRD) with a Outperform rating and announces Price Target of $18.
Third Harmonic Bio (NASDAQ:THRD) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.31) by 35.48 percent.
Third Harmonic Bio (NASDAQ:THRD) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.31) by 45.16 percent. This is a 52.78 percent increase over losses of $(0.36) per share from the same period last year.
Third Harmonic Bio (NASDAQ:THRD) reported its Q4 earnings results on Tuesday, March 26, 2024 at 08:05 AM. Here's what investors need to know about the announcement. Earnings Third Harmonic Bio beat estimated earnings by 45.0%, reporting an EPS of $-0.17 versus an estimate of $-0.31. Revenue was down $0 from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.08 which was followed by a 1.0% increase in the share price the next day. ** Listen to the earnings announcement yourself by clicking here. ** To track all earnings releases for Third Harmonic Bio visit their earnings calendar here. This article was generated by Benzinga's automated content e
Summary of Financial ResultsCash Position: Cash and cash equivalents totaled $269.1 million as of December 31, 2023. Based on the company's current operating plan, Third Harmonic Bio believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements through at least 2026.R&D Expenses: Research and development (R&D) expenses decreased to $5.9 million for the three months ended December 31, 2023, from $9.3 million for the same period in 2022. R&D expenses for the year ended December 31, 2023 decreased to $24.0 million, from $24.4 million for the same period in 2022. The decreases were primarily due to decreases in develop
Chris brings extensive enterprise-level leadership experience in business development, commercial operations, and corporate strategy IND-enabling toxicology studies of THB335 nearing completion; Pre-IND interaction with the U.S. FDA now completeProgram remains on track to file a U.S. IND and initiate a Phase 1 study of THB335 during the first half of 2024SAN FRANCISCO, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Christopher Murphy as Chief Financial and Business Officer. Chris brings extensive experience in business development
Third Harmonic Bio (NASDAQ:THRD) reported its Q3 earnings results on Thursday, November 9, 2023 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Third Harmonic Bio missed estimated earnings by 125.93%, reporting an EPS of $-0.61 versus an estimate of $-0.27. Revenue was down $0 from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.11 which was followed by a 0.64% increase in the share price the next day. ** Listen to the earnings announcement yourself by clicking here. ** To track all earnings releases for Third Harmonic Bio visit their earnings calendar here. This article was generated by Benzinga's automated c
Third Harmonic Bio (NASDAQ:THRD) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.27) by 125.93 percent. This is a 32.22 percent increase over losses of $(0.90) per share from the same period last year.
SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Geoff McDonough, M.D., to its Board of Directors. "Geoff is an outstanding addition to our board, bringing broad operational leadership and a depth of clinical and commercial experience that will benefit our work greatly as we advance our lead product candidate, THB335, into clinical trials for chronic spontaneous urticaria," said Natalie Holles, Chief Executive Officer of Third Harmonic Bio. "Beyond his expertise, Geoff is an excellent cultural fit with our organ
Chris brings extensive enterprise-level leadership experience in business development, commercial operations, and corporate strategy IND-enabling toxicology studies of THB335 nearing completion; Pre-IND interaction with the U.S. FDA now complete Program remains on track to file a U.S. IND and initiate a Phase 1 study of THB335 during the first half of 2024 SAN FRANCISCO, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Christopher Murphy as Chief Financial and Business Officer. Chris brings extensive experience in business de
SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that management will participate in the following upcoming conferences: Natalie Holles, Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at 3:00 p.m. ESTChris Murphy, Chief Financial and Business Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 11:00 a.m. GMT / 6:00 a.m. E
THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q'25 Strong financial position with cash and cash equivalents totaling $296.1 million as of September 30, 2024 SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory and gastrointestinal inflammatory diseases, today announced financial results for the third quarter September 30, 2024. "As the Phase 1 clinical trial of our development candidate THB335 continues toward an anticipated data readout in the first quarter of 2025, we are also making excellent progress i
SAN FRANCISCO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in fireside chats at the following upcoming conferences: Stifel 2024 Virtual Immunology and Inflammation Summit on Wednesday, September 18, 2024, at 9:00 a.m. ETTD Cowen Virtual Chronic Urticaria Summit on Friday, September 20, 2024, at 3:00 p.m. ET A live audio webcast will be available within the Investors & Media section of the Third Harmonic Bio website. An archiv
SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in a fireside chat at the following upcoming conferences: Morgan Stanley 22nd Healthcare Conference on Wednesday, September 4, 2024, at 9:15 a.m. ETStifel 2024 Virtual Immunology and Inflammation Summit on Wednesday, September 18, 2024, at 9:00 a.m. ET A live audio webcast will be available within the Investors & Media section of the Third Harmonic Bio website. An
THB335 Phase 1 SAD/MAD clinical trial progressing; study now on track to report clinical results in 1Q'25 Strong financial position with cash and cash equivalents totaling $255.3 million as of June 30, 2024 SAN FRANCISCO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory and gastrointestinal inflammatory diseases, today announced financial results for the second quarter June 30, 2024, along with business updates. "We are making excellent progress in our Phase 1 SAD/MAD clinical trial of THB335 and
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer, Natalie Holles, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 7:30 a.m. ET. A live audio webcast will be available within the Investors & Media section of the Third Harmonic Bio website. An archived replay will be accessible for 90 days following the event. About Third Harmonic Bio, Inc.Third Harmonic Bio is a clinical stage biopharma
U.S. FDA clears Investigational New Drug application for THB335 Phase 1 SAD/MAD clinical trial initiated and subject screening underway, with results expected during 1H'25 Strengthened leadership team with the appointment of Christopher J. Dinsmore, Ph.D., to Chief Scientific Officer, Dennis Dean, Ph.D., to Chief Non-Clinical Development Officer, and the promotion of Jennifer Dittman to Chief Development Operations Officer Strong financial position with cash and cash equivalents totaling $262.8 million as of March 31, 2024 SAN FRANCISCO, May 15, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a clinical stage biopharmaceutical company focused on advancing the next wav
SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Geoff McDonough, M.D., to its Board of Directors. "Geoff is an outstanding addition to our board, bringing broad operational leadership and a depth of clinical and commercial experience that will benefit our work greatly as we advance our lead product candidate, THB335, into clinical trials for chronic spontaneous urticaria," said Natalie Holles, Chief Executive Officer of Third Harmonic Bio. "Beyond his expertise, Geoff is an excellent cultural fit with our organ
U.S. IND filed for THB335 with anticipated clinical trial start during 2Q'24 Strong financial position with cash and cash equivalents totaling $269.1 million as of December 31, 2023 SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023. "Our team's execution continues to be outstanding, with the filing of our U.S. IND for THB335 ahead of our internal timelines for submission," said Natalie Holles, Chief Executive Officer of Third Harmonic Bio. "We look forw
SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced that Chief Executive Officer, Natalie Holles, will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024, at 1:30 p.m. ET. A live audio webcast will be available within the Investors & Media section of the Third Harmonic Bio website. An archived replay will be accessible for 90 days following the event. About Third Harmonic Bio, Inc.Third Harmonic Bio is a biopharmaceutical company focused on advancing the next wave of medicine for